All Hong Kong stocks quotes are at least 15 minutes delayed.
02142
HBM HOLDINGS-B
HKD
11.3300.300
(2.72%)
1D
AI Analysis
High
11.450
Open
11.240
VWAP
11.26
Vol
1.20M
Mkt Cap
11.95B
Low
11.050
Amount
13.51M
EV/EBITDA(TTM)
12.01
Total Shares
869.46M
EV
972.47M
EV/OCF(TTM)
17.59
P/S(TTM)
9.64
Hbm Holdings Ltd is an investment holding company primarily engaged in the business of developing innovative therapeutics in the fields of immuno-oncology and immunology diseases. The Company’s products primarily include BATOCLIMAB (HBM9161), HBM9378, HBM7020, TCE Program, PORUSTOBART (HBM4003), HBM7022 and others. The products are primarily used to treat generalized myasthenia gravis (gMG), chronic obstructive pulmonary disease (COPD), asthma, autoimmune diseases, melanoma, colorectal carcinoma (CRC) and solid tumors. The Company provides next-generation antibody and biotherapeutic solutions through proprietary antibody technology platforms including Harbour Mice, HBICE, HBICA and single B cell cloning platform.
Show More
News
Money Flow
Over the past 66 trading days, overall net money flow is -15.04M, with retail investors contributing -386.90K and major investors adding -10.37M.
Net Buy $ Volume
Net Sell $ Volume
No data
Valuation Metrics
Forward PE
N/A
5Y Average PE
0.96
Current PE
22.49
Overvalued PE
19.71
Undervalued PE
-17.79
Forward EV/EBITDA
N/A
5Y Average EV/EBITDA
2.69
Current EV/EBITDA
12.92
Overvalued EV/EBITDA
11.73
Undervalued EV/EBITDA
-6.35
Forward PS
N/A
5Y Average PS
12.98
Current PS
8.57
Overvalued PS
34.65
Undervalued PS
-8.69
Financials
AI Analysis
Annual
Quarterly
Trading Trends
Daily
Monthly
Buyback
Short Selling
People Also Watch